Oncopeptides (STO:ONCO) announced today that it launched its Pepaxto drug for treating relapsed or refractory multiple myeloma. Boston-based Oncopeptides’ Pepaxto (melphalan flufenamide), which received accelerated FDA approval on Feb. 26, is now commercially available and the first patients are being treated with the drug, according to a news release. Pepaxto received approval in combination with […]
Savara closes $130M offering
Savara (NSDQ:SVRA) announced today that it closed its previously announced public offering with proceeds reaching approximately $130 million. Austin, Texas-based Savara last week announced the offering of 45.8 million shares of its common stock to the public for $1.45 per share, expecting proceeds of $113 million. However, the company today said in a news release […]
Bicara Therapeutics launches with $40M investment
Bicara Therapeutics announced today that it has launched with a $40 million investment from Biocon Limited. Cambridge, Mass.-based Bicara’s financing is earmarked for the advancement of its pipeline of first-in-class bifunctional antibodies developed between an engineering team in Bangalore, India, and the Cambridge-based executive team, according to a news release. Bicara’s pipeline includes tumor-targeted antibodies […]
Aurinia touts cost-effectiveness study of oral treatment for lupus nephritis
Aurinia Pharmaceuticals (NSDQ:AUPH) announced today that it received a favorable assessment of the cost-effectiveness of Lupkynis. Victoria, British Columbia-based Aurinia’s Lukynis (voclosporin) was evaluated in an independent analysis by the Institute for Clinical and Economic Review (ICER) in a revised evidence report issued on March 12, 2021, according to a news release. The evaluation found […]
AVEO to collaborate with Bristol Myers Squibb on renal cell carcinoma drugs
AVEO Oncology (NSDQ:AVEO) announced today that it entered into a clinical trial collaboration with Bristol Myers Squibb. Boston-based AVEO’s collaboration and supply agreement with Bristol Myers Squibb is slated to evaluate Fotivda (tivozanib) in combination with Opdivo (nivolumab), an anti-PD-1 therapy developed by Bristol Myers Squibb. The drugs will be evaluated in a pivotal Phase […]
Injectable medicine technology developer ApiJect Systems appoints new COO
ApiJect Systems announced that Raymond J. Guidotti joined the company as its new chief operating officer. Stamford, Conn.-based ApiJect, which develops technologies for vaccines and injectable medicines to be filled, finished and delivered, made the personnel move effective on March 1, 2021, according to a news release. Guidotti is a veteran of more than 30 […]
Ocular Therapeutix reports Q4 misses
Ocular Therapeutix (NSDQ:OCUL) reported fourth-quarter results that missed the consensus forecast. The Bedford, Mass.–based eye disease therapeutic developer posted losses of –$85.6 million, or –$1.21 per share, on sales of $7.3 million for the three months ended Dec. 31, 2020, for a massive bottom-line slide from losses of –$26 million last year despite more than […]
Savara prices $113M offering
Savara (NSDQ:SVRA) announced today that it priced an underwritten public offering of common stock at approximately $113 million. Austin, Texas-based Savara — an orphan lung disease treatment company with an inhaled formulation of recombinant human GM-CSF — is offering nearly 45.8 million shares of its common stock to the public for $1.45 per share, according to […]
AFYX Therapeutics touts study results for biodegradable oral adhesive patch
AFYX Therapeutics announced today that a study observed successful transmucosal delivery of a corticosteroid with its Rivelin patch. The Rivelin clobetasol patch (Rivelin-CLO) is a novel adhesive patch designed to deliver a therapeutic agent to wet tissue surfaces. The study, published in The European Journal of Oral Sciences, was the first to show the successful […]
Xeris Pharmaceuticals prices $27M offering
Xeris Pharmaceuticals (NSDQ:XERS) announced today that it priced a registered direct offering of common stock at $27 million. Chicago-based Xeris is offering nearly 6.6 million shares of common stock to funds managed by Deerfield Management Company, which are existing investors in the company, according to a news release. The offering is priced at $4.12 per share, […]
